Advanced search
Start date
Betweenand

Murine Leukemia/Lymphoid Lymphoma models for evaluating antitumor effects of CAR-CD19-modified T cells

Grant number: 17/09491-8
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): June 01, 2017
Effective date (End): November 30, 2018
Field of knowledge:Biological Sciences - Immunology
Principal Investigator:Dimas Tadeu Covas
Grantee:Marcelo de Souza Fernandes Pereira
Home Institution: Hemocentro de Ribeirão Preto. Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Secretaria da Saúde (São Paulo - Estado). Ribeirão Preto , SP, Brazil
Associated research grant:13/08135-2 - CTC - Center for Cell-Based Therapy, AP.CEPID

Abstract

Most of B-cell neoplasms are responsive to chemotherapy, however, in some patients this treatment shown a non-effective response presenting recurrence. Immunotherapies have been described as an alternative for cancer treatment, been a high innovative technology in which cells of the immune system can be genetically engineered with Chimeric Antigen Receptors (CAR). These cells perform a specific recognition of cancer cells independent of histocompatibility complex.Different types of CARs have been developed to recognize tumor cell specific antigens. Usually, anti-CD19 CAR-modified T cells have been successfully applied in patients with B cell neoplasms, such as Acute Lymphoblastic Leukemia (ALL) and Burkitt's Lymphoma (LB). This approach has shown promising results in clinical trials. Although several groups abroad have demonstrated the efficiency of this treatment in clinical trials, it is important to implant this therapeutic technology in Brazil, and the generation of a murine model of B-cell lymphoid neoplasia as well as, which will be really important to determining The therapeutic potential of CAR-T-CD19 cells in xenogeneic models. (AU)